Vitura Health Limited

As of June 30, 2025, Vitura Health Limited carries a market capitalization of 41.06M, placing it among publicly traded companies globally. Its enterprise value stands at 44.85M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vitura Health Limited's next confirmed earnings release is scheduled for March 2, 2027.

As of June 30, 2025, Vitura Health Limited has 662.25M shares outstanding.

As of June 30, 2025, Vitura Health Limited trades at a trailing price-to-earnings ratio of 11.37. The price-to-sales ratio is 0.30, and the price-to-book ratio stands at 0.85.

As of June 30, 2025, Vitura Health Limited trades at an EV/EBITDA multiple of 5.96 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.36 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.56 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 44.85M versus a market cap of 41.06M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Vitura Health Limited maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.14, indicating elevated leverage, while an interest coverage ratio of 8.79 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2025, Vitura Health Limited posted a return on equity (ROE) of 7.64, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.26 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.53, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.60, useful for judging operating efficiency across full business cycles. Inventory turnover of 16.43 indicates how many times Vitura Health Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2025, Vitura Health Limited recorded 1.64M in income tax expense. That works out to an effective tax rate of 34.93, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.71M, leaving 3.32M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Vitura Health Limited's stock has declined approximately 73.91% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.04.

Over the twelve months ended June 30, 2025, Vitura Health Limited generated 124.04M in revenue and converted that into 3.32M in net income, yielding earnings per share of 0.01. EBITDA reached 7.52M, while operating income came in at 5.24M.

As of June 30, 2025, Vitura Health Limited holds 7.58M in cash and equivalents against 11.97M in total debt, resulting in a net debt position of 1.64M. Total book value stands at 48.20M, with working capital of 6.88M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, Vitura Health Limited posted a gross margin of 27.21, reflecting its pricing power and cost economics. The operating margin of 4.23 and net profit margin of 2.68 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -18.10, meaning Vitura Health Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2025, Vitura Health Limited has an Altman Z-Score of 5.76, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.